
FDA clears TuHURA's TBS-2025 antibody for Phase 1b trial in resistant AML patients
TuHURA Biosciences received FDA clearance to start a Phase 1b trial for TBS-2025, a VISTA-inhibiting antibody targeting relapsed/refractory mutNPM1 Acute Myeloid Leukemia (AML) patients who failed menin inhibitor therapy. This trial will assess safet...





